先天性免疫缺陷成年患者COVID-19结局的病例系列研究

IF 0.3 Q4 IMMUNOLOGY
Jenny Garkaby, O. Scott, Laura Abrego Fuentes, L. Vong, Jessica Willett-Pachul, Myra Pereira, V. Kim, C. Roifman
{"title":"先天性免疫缺陷成年患者COVID-19结局的病例系列研究","authors":"Jenny Garkaby, O. Scott, Laura Abrego Fuentes, L. Vong, Jessica Willett-Pachul, Myra Pereira, V. Kim, C. Roifman","doi":"10.14785/lymphosign-2022-0009","DOIUrl":null,"url":null,"abstract":"Background: Since the onset of the COVID-19 pandemic, a main challenge for clinicians and public health decision-makers has revolved around risk stratification in vulnerable populations, in particular individuals with inborn errors of immunity (IEI). However, available reports of the clinical course of COVID-19 in patients with IEI show wide variability, from a complete lack of symptoms to severe and complicated disease. Objective: To present the clinical features and outcomes of SARS-CoV-2 infection in adult patients with IEI. Methods: A retrospective chart review involving patient characteristics and clinical course of SARS-CoV-2 infection between December 2021-July 2022. Results: Ten adult patients with IEI followed in our center were diagnosed with COVID-19, as determined by RT-PCR or rapid antigen test. IEI in this cohort included both humoral, combined immunodeficiencies and phagocytic defects, with an underlying lung comorbidity identified in 3 patients. Symptoms were mostly mild and self-limiting. No severe outcomes, complications or mortality were noted in this study. Conclusions: We suggest that patients affected by a wide range of both humoral and combined IEI may demonstrate resilience, while highlighting the possible protective effects of vaccination and immunoglobulin replacement in this population.","PeriodicalId":53881,"journal":{"name":"LymphoSign Journal-The Journal of Inherited Immune Disorders","volume":" ","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Case series of COVID-19 outcomes in adult patients with inborn errors of immunity\",\"authors\":\"Jenny Garkaby, O. Scott, Laura Abrego Fuentes, L. Vong, Jessica Willett-Pachul, Myra Pereira, V. Kim, C. Roifman\",\"doi\":\"10.14785/lymphosign-2022-0009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Since the onset of the COVID-19 pandemic, a main challenge for clinicians and public health decision-makers has revolved around risk stratification in vulnerable populations, in particular individuals with inborn errors of immunity (IEI). However, available reports of the clinical course of COVID-19 in patients with IEI show wide variability, from a complete lack of symptoms to severe and complicated disease. Objective: To present the clinical features and outcomes of SARS-CoV-2 infection in adult patients with IEI. Methods: A retrospective chart review involving patient characteristics and clinical course of SARS-CoV-2 infection between December 2021-July 2022. Results: Ten adult patients with IEI followed in our center were diagnosed with COVID-19, as determined by RT-PCR or rapid antigen test. IEI in this cohort included both humoral, combined immunodeficiencies and phagocytic defects, with an underlying lung comorbidity identified in 3 patients. Symptoms were mostly mild and self-limiting. No severe outcomes, complications or mortality were noted in this study. Conclusions: We suggest that patients affected by a wide range of both humoral and combined IEI may demonstrate resilience, while highlighting the possible protective effects of vaccination and immunoglobulin replacement in this population.\",\"PeriodicalId\":53881,\"journal\":{\"name\":\"LymphoSign Journal-The Journal of Inherited Immune Disorders\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2022-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"LymphoSign Journal-The Journal of Inherited Immune Disorders\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14785/lymphosign-2022-0009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"LymphoSign Journal-The Journal of Inherited Immune Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14785/lymphosign-2022-0009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:自2019冠状病毒病大流行爆发以来,临床医生和公共卫生决策者面临的主要挑战是弱势人群的风险分层,特别是存在先天性免疫错误(IEI)的个体。然而,现有的关于IEI患者的COVID-19临床病程的报告显示了广泛的差异,从完全没有症状到严重和复杂的疾病。目的:了解成人IEI患者SARS-CoV-2感染的临床特点及转归。方法:回顾性分析2021年12月至2022年7月期间SARS-CoV-2感染的患者特征和临床病程。结果:本中心随访的10例成人IEI患者经RT-PCR或快速抗原检测均确诊为COVID-19。该队列中的IEI包括体液、联合免疫缺陷和吞噬缺陷,并在3例患者中发现潜在的肺部合并症。症状大多轻微且自限性。本研究未发现严重的结局、并发症或死亡率。结论:我们认为,受到广泛体液性和联合性IEI影响的患者可能表现出恢复能力,同时强调了疫苗接种和免疫球蛋白替代在这一人群中可能的保护作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Case series of COVID-19 outcomes in adult patients with inborn errors of immunity
Background: Since the onset of the COVID-19 pandemic, a main challenge for clinicians and public health decision-makers has revolved around risk stratification in vulnerable populations, in particular individuals with inborn errors of immunity (IEI). However, available reports of the clinical course of COVID-19 in patients with IEI show wide variability, from a complete lack of symptoms to severe and complicated disease. Objective: To present the clinical features and outcomes of SARS-CoV-2 infection in adult patients with IEI. Methods: A retrospective chart review involving patient characteristics and clinical course of SARS-CoV-2 infection between December 2021-July 2022. Results: Ten adult patients with IEI followed in our center were diagnosed with COVID-19, as determined by RT-PCR or rapid antigen test. IEI in this cohort included both humoral, combined immunodeficiencies and phagocytic defects, with an underlying lung comorbidity identified in 3 patients. Symptoms were mostly mild and self-limiting. No severe outcomes, complications or mortality were noted in this study. Conclusions: We suggest that patients affected by a wide range of both humoral and combined IEI may demonstrate resilience, while highlighting the possible protective effects of vaccination and immunoglobulin replacement in this population.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
12.50%
发文量
12
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信